Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost in peripheral arterial disease with chronic limb ischemia: oxidative stress and erectile dysfunction
2008-006304-38Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iloprost in arteriosclerosis obliterans, chronic limb-threatening ischaemia (CLTI) and erectile dysfunction (ED), sponsored by Policlinico Gemelli. Primary endpoints: Change in oxidative stress and Change in erectile dysfunction. Started Nov 2008; status: terminated.
02
Drugs
iloprost
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischaemia (CLTI)erectile dysfunction (ED)
Beyond the preview
Go deeper on 2008-006304-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006304-38.